ENDRA Life Sciences (NASDAQ:NDRA) Issues Quarterly Earnings Results

ENDRA Life Sciences (NASDAQ:NDRA) issued its earnings results on Friday. The company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.14, FiscalAI reports.

ENDRA Life Sciences Trading Down 12.0%

NASDAQ:NDRA traded down $0.69 during trading hours on Friday, hitting $5.05. The company had a trading volume of 44,977 shares, compared to its average volume of 18,612. The company has a 50-day moving average of $4.57 and a 200 day moving average of $4.74. The company has a market cap of $6.26 million, a P/E ratio of -0.57 and a beta of -0.11. ENDRA Life Sciences has a 1 year low of $2.91 and a 1 year high of $11.96.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, ENDRA Life Sciences presently has a consensus rating of “Hold” and a consensus target price of $30.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.